Engineered antibodies currently represent over 30% of biopharmaceuticals in clinical trials and their total worldwide sales continue to increase significantly. There is a strong focus on those issues related to the production of intrabodies, bispecific antibody and antibody fragments and also to novel applications in cancer immunotherapy.

356 pages, biography

Media	Books Paperback Book (Book with soft cover and glued back)
Released	July 15, 2013
ISBN13	9789400736139
Publishers	Springer
Pages	346
Dimensions	155 × 235 × 19 mm · 508 g
Editor	Al-Rubeai, Mohamed

Show all

More by Mohamed Al-rubeai

See all of Mohamed Al-rubeai ( e.g. Hardcover Book and Paperback Book )